STOCK TITAN

Legend Biotech Announces Participation in Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

SOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Event: BMO Biopharma Spotlight Series: Oncology Day (Virtual)
Fireside Chat Date & Time: Wednesday, November 9, 2022 at 1:30pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Cowen 6th Annual IO Next Summit (Virtual)
Fireside Chat Date & Time: Friday, November 11, 2022 at 1:10pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: JP Morgan Equity Opportunities Forum
Location: Miami, Florida
Date: Monday, November 14, 2022

Event: Jefferies London Healthcare Conference
Location: London
Fireside Chat Date & Time: Thursday, November 17, 2022 at 2:40pm GMT
Presenter: Ying Huang, Ph.D., CEO

Event: Piper 34th Annual Healthcare Conference
Location: New York, New York
Fireside Chat Date & Time: Tuesday, November 29, 2022 at 3:00pm ET
Presenter: Ying Huang, Ph.D., CEO

Event: Evercore ISI 5th Annual HealthCONx Conference (Virtual)
Fireside Chat Date & Time: Wednesday, November 30, 2022 at 9:40am ET
Presenter: Ying Huang, Ph.D., CEO

About Legend Biotech

Legend Biotech is a global biotechnology company dedicated to treating, and one day curing, life-threatening diseases. Headquartered in Somerset, New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.

Learn more at www.legendbiotech.com and follow us on Twitter and LinkedIn.

Investor Contacts:

Joanne Choi, Senior Manager, Investor Relations, Legend Biotech

joanne.choi@legendbiotech.com



Crystal Chen, Manager, Investor Relations, Legend Biotech

crystal.chen@legendbiotech.com



Press Contact:

Tina Carter, Corporate Communications Lead, Legend Biotech

tina.carter@legendbiotech.com

(908) 331-5025

Source: Legend Biotech

Legend Biotech Corporation American Depositary Shares

NASDAQ:LEGN

LEGN Rankings

LEGN Latest News

LEGN Stock Data

8.36B
158.77M
1.32%
48.72%
5.49%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Somerset

About LEGN

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated a strong pipeline of chimeric antigen receptor(car) product candidates to treat a wide variety of liquid and solid tumors. our ambition to succeed in the cars field has been substantially fulfilled by the latest clinical trial results that we have achieved a great clinical success in treating multiple myeloma, a previously incurable blood cancer. by applying one of our proprietary car-t technology, we have reached a promising result in the clinical research for the enrolled patient group bearing refractory and relapsed multiple myeloma. legend biotech corporation is founded on the vision that the previous incurable previousincurable cancer will be safely and effectively treated with fine-tuning products generated on our innovative technology platform. we take o